ライフサイエンスコーパス: nmol

1 The limit of detection of the method was 1.0 nmol/L, which is much less than the required MRL in EU r

2 on in a dose-dependent manner (0.001 to 10.0 nmol/L).

3 ol: 55.8 +/- 12.3 nmol/L; EAR: 64.1 +/- 10.0 nmol/L; and RDA: 63.7 +/- 12.4 nmol/L; P < 0.05) than th

4 han the required MRL in EU regulations (12.0 nmol/L).

5 compared with the RG diet [-6.8 nmol/g (13.0 nmol/g) dry weight for WG compared with 1.8 nmol/g (12.3

6 l/L (7.4, 23.3 nmol/L) (P < 0.0003) and 16.0 nmol/L (8.0, 23.9 nmol/L) ( P < 0.0001)], the vitamin D2

7 n provinces (2011 vs 2013 median IC50s: 20.0 nmol/L [IQR 13.7-29.0] vs 39.2 nmol/L [32.8-48.1] for Ra

8 6.5 nmol/L), and 25.5 nmol/L (IQR: 17.2-40.0 nmol/L), respectively, in RTRs (all P < 0.001).

9 : 29-60 nmol/L), 40.1 nmol/L (IQR: 33.0-48.0 nmol/L), and 19.1 nmol/L (IQR: 14.5-24.9 nmol/L), respec

10 and smoking (adjusted mean difference: -7.0 nmol/L; 95% CI: -10.5, -3.6 nmol/L) were negative predic

11 rence: -0.018 nmol/L; 95% CI: -0.026, -0.009 nmol/L).

12 ternal age (adjusted mean difference: -0.018 nmol/L; 95% CI: -0.026, -0.009 nmol/L).

13 ction limit was 0.4 nM P, equivalent to 0.03 nmol P m(-3) in atmospheric particles.

14 PCKm(28.0 +/- 3.9 mum) andVmax(1.08 +/- 0.05 nmol/min/mg), which have not previously been reported.Km

15 re 25(OH)D3 (adjusted mean difference: 0.052 nmol/L; 95% CI: 0.050, 0.053 nmol/L) and maternal age (a

16 fference: 0.052 nmol/L; 95% CI: 0.050, 0.053 nmol/L) and maternal age (adjusted mean difference: -0.0

17 A LOD of 0.60 +/- 0.01 nM (4.80 +/- 0.08 nmol kg(-1) sputum) is reached for both biomarker target

18 imal ablation, topical administration of 0.1 nmol CFTRact-K089 3 times daily restored tear volume to

19 plied using PSMA(HBED) amounts as low as 0.1 nmol.

20 Limits of detection ranging from 0.4 to 1.1 nmol/g brain tissue were established for the different G

21 re 10.7 nmol/L (SD 2.3) at baseline and 11.1 nmol/L (3.2) post-intervention and free testosterone con

22 bo (57.0 +/- 21.3 compared with 1.9 +/- 15.1 nmol/L, respectively; P = 0.02).

23 0.1 nmol/L (IQR: 33.0-48.0 nmol/L), and 19.1 nmol/L (IQR: 14.5-24.9 nmol/L), respectively, in healthy

24 asma 25(OH)D concentration was 68.7 +/- 19.1 nmol/L.

25 d xylose uptake rates (Vmax = 186.4 +/- 20.1 nmol*min(-1)*mg(-1)) that allows the S. cerevisiae strai

26 in chicken, pork and beef (2.8, 3.6 and 3.1 nmol/mg of protein, respectively).

27 d blood cell folate concentrations were 35.1 nmol/L (range: 21-47 nmol/L) and 956 nmol/L (range: 305-

28 ons were 41 nmol/L (IQR: 29-60 nmol/L), 40.1 nmol/L (IQR: 33.0-48.0 nmol/L), and 19.1 nmol/L (IQR: 14

29 Vihear, and 19.6 nmol/L [11.9-33.9] vs 81.1 nmol/L [61.3-113.1] for Pursat; all p</=10(-3); Kruskal-

30 acerebroventricular (icv) infusion of NPY (1 nmol/2 microl) prolonged retention of non-social (object

31 and 6.2 %ID/g, respectively), for doses of 1 nmol.

32 ocaine-seeking after intra-CeA SB-334867 (10 nmol) administration.

33 Vs menthol and methyl salicylate at 1 and 10 nmol.ml(-1) improved many performance aspects of the fun

34 of age (e.g., serum folate concentration <10 nmol/L and RBC folate concentration <340 nmol/L derived

35 Renal survival increased 8.2% per 10 nmol/L increase in 25(OH)D (P=0.03), independent of eGFR

36 um 25-hydroxyvitamin D concentration (per 10-nmol/L increment: adjusted odds ratio (aOR) = 0.95, 95%

37 nmol/L, 75-99 nmol/L (reference), and >/=100 nmol/L.

38 ning high (150 nmol or 3450 mg), medium (100 nmol or 2300 mg), and low (50 nmol or 1150 mg) amounts o

39 iodothyronine (100 pmol/L) or thyroxine (100 nmol/L).

40 n in the warfarin group (geometric mean 1086 nmol/L per min, 95% CI 957-1233 vs 548, 484-621, treatme

41 o showed the largest 25(OH)D increases (7-11 nmol/L) were older, female, non-Hispanic white, and vita

42 ce N2O concentrations much higher (up to 115 nmol L(-1)) than those previously reported for the Atlan

43 (4x12Q4W), or grass allergen peptides at 12 nmol at 2-week intervals for a total of 8 doses (8x12Q2W

44 oses (8x6Q2W), grass allergen peptides at 12 nmol at 4-week intervals for a total of 4 doses (4x12Q4W

45 The men, with a total testosterone <12 nmol/L, were treated with 15 g soy protein containing 66

46 of precursor, 6 GBq of (177)Lu activity/120 nmol of precursor, 7.4 GBq of (177)Lu activity/150 nmol

47 lues in categories between 40 nmol/L and 120 nmol/L.

48 fferent pretargeting time intervals (C1: 120 nmol TF2, 6 nmol IMP288, 24 h; C2: 120 nmol TF2, 6 nmol

49 : 120 nmol TF2, 6 nmol IMP288, 24 h; C2: 120 nmol TF2, 6 nmol IMP288, 30 h; C3: 120 nmol TF2, 6 nmol

50 : 120 nmol TF2, 6 nmol IMP288, 30 h; C3: 120 nmol TF2, 6 nmol IMP288, 42 h; C4: 120 nmol TF2, 3 nmol

51 : 120 nmol TF2, 6 nmol IMP288, 42 h; C4: 120 nmol TF2, 3 nmol IMP288, 30 h; and C5: 60 nmol TF2, 3 nm

52 Accordingly, risk >/=120 nmol/L could not be evaluated (i.e., n = 7 and ndeaths =

53 tatus (C-reactive protein >3.0 mug/mL or 120 nmol/L), respectively.

54 women with serum 25(OH)D between 50 and 125 nmol/L when models were further adjusted for season of b

55 verse effects of 25(OH)D concentrations >125 nmol/L were observed.

56 found to be 71.2 +/- 17 mumand 1.42 +/- 0.14 nmol/min/mg, respectively.

57 DSLNT) concentrations ranged from 216 +/- 14 nmol/mL (in Sweden) to 870 +/- 68 nmol/mL (in rural Gamb

58 mol/L higher than nonconsumers (n = 229) (14 nmol/L; 95% CI: 12, 16 nmol/L) (P < 0.001).

59 Reactions were conducted with 145 nmol of the substrate using a 50 muL microsyringe as the

60 recursor, or 9.3 GBq of (177)Lu activity/150 nmol of precursor (10 patients per group) every 2 mo.

61 f precursor, 7.4 GBq of (177)Lu activity/150 nmol of precursor, or 9.3 GBq of (177)Lu activity/150 nm

62 in random order, diets containing high (150 nmol or 3450 mg), medium (100 nmol or 2300 mg), and low

63 L for standard-dose and 1040, 1494, and 1585 nmol/L for double-dose chloroquine.

64 +/- SEM: 473 +/- 55 compared with 103 +/- 16 nmol/mL, respectively; P < 0.05), and disialyllacto-N-te

65 nsumers (n = 229) (14 nmol/L; 95% CI: 12, 16 nmol/L) (P < 0.001).

66 7 nmol/mmol) versus 7.58 nmol/mmol (SD, 6.17 nmol/mmol), with a mean difference of 0.67 nmol/mmol (95

67 ivalents, with a quantification limit of 0.2 nmol.

68 fference: -19.3 nmol/L; 95% CI: -25.4, -13.2 nmol/L) and smoking (adjusted mean difference: -7.0 nmol

69 amin D concentrations (154.5 nmol/L vs. 15.2 nmol/L in active vs. placebo arms, respectively; 95% con

70 roup [Delta (95% CI): 16.3 nmol/L (8.4, 24.2 nmol/L) (P < 0.0001) and 16.9 nmol/L (9.0, 24.8 nmol/L)

71 a C-reactive protein level of 29 mg/L (276.2 nmol/L) (normal value, <10 mg/L [95.2 nmol/L]), and an e

72 usted to achieve concentrations of 17.3-31.2 nmol/L.

73 n IC50s: 20.0 nmol/L [IQR 13.7-29.0] vs 39.2 nmol/L [32.8-48.1] for Ratanakiri, 19.3 nmol/L [15.1-26.

74 oup [Delta (95% CI): 42.3 nmol/L (34.4, 50.2 nmol/L) (P < 0.0001) and 42.9 nmol/L (35.0, 50.8 nmol/L)

75 Ratanakiri, 19.3 nmol/L [15.1-26.2] vs 66.2 nmol/L [49.9-83.0] for Preah Vihear, and 19.6 nmol/L [11

76 [924.8 nmol/L]; normal level, <8 mg/L [<76.2 nmol/L]]) levels were chronically elevated at serum test

77 respectively, but decreased to 49.8 and 93.2 nmol/L when treated in combination with rubone, demonstr

78 (276.2 nmol/L) (normal value, <10 mg/L [95.2 nmol/L]), and an erythrocyte sedimentation rate of 35 mm

79 ot by the Y2 receptor antagonist BIIE0246 (2 nmol/2 microl).

80 ptor antagonist BIBO3304 trifluoroacetate (2 nmol/2 microl), but not by the Y2 receptor antagonist BI

81 Microinjections of SB-334867 (20 nmol) bilaterally into the CeA significantly reduced coc

82 d for eight 25(OH)D (nmol/L) categories: <20 nmol/L, 20-29 nmol/L, 30-39 nmol/L, 40-49 nmol/L, 50-59

83 itamin B-6 deficiency was defined as PLP <20 nmol/L, and insufficiency as PLP 20-30 nmol/L.

84 ould be used on an extremely small scale (20 nmol) with a high radiochemical yield.

85 (n = 1017) among supplement nonusers was 20 nmol/L (95% CI: 19, 21 nmol/L), which was 6 nmol/L highe

86 Carbamylcholine (CCh, 200 nmol l(-1) , n = 9) significantly (P < 0.05) reduced hea

87 We found that PCoA concentration < 200 nmol/mg mito protein resulted in low H2O2 emission flux,

88 ement nonusers was 20 nmol/L (95% CI: 19, 21 nmol/L), which was 6 nmol/L higher than nonconsumers (n

89 y 600 nmol m(-2) and of methylmercury by 214 nmol m(-2) in the Gotland Deep, probably via attachment

90 1-47 nmol/L) and 956 nmol/L (range: 305-2319 nmol/L), respectively.

91 (means +/- SEM: 382 +/- 35 versus 73 +/- 24 nmol L(-1) d(-1) , Mann-Whitney U-test p < 0.0001), and

92 05) and HVA concentrations by a median of 25 nmol/L (IQR 11-48; p=0.012); however, there was no signi

93 and 14.7-18.6 mg/cm(2), respectively, per 25 nmol/L 25(OH)D]; when 25(OH)D at all 4 ages was included

94 ipants with baseline 25(OH)D of less than 25 nmol/L (aIRR 0.33, 0.11-0.98; p=0.046; 92 participants i

95 x and Mars analog materials enriched with 25 nmol of each targeted organic molecule.

96 r was created by impregnating 2.5 muL (0.285 nmol) of fluorescein mercury acetate (FMA) onto the surf

97 EFCs, which resulted in the formation of 286 nmol NH3 mg(-1) MoFe protein, corresponding to a Faradai

98 G-CSF (0.49 nmol/L/min) versus placebo (0.29 nmol/L/min).

99 (OH)D (nmol/L) categories: <20 nmol/L, 20-29 nmol/L, 30-39 nmol/L, 40-49 nmol/L, 50-59 nmol/L, 60-74

100 the median plasma PLP concentrations were 29 nmol/L (17-50 nmol/L) and 41 nmol/L (29-60 nmol/L), resp

101 tively, in healthy controls compared with 29 nmol/L (IQR: 17-50 nmol/L), 61.5 nmol/L (IQR: 45.6-86.5

102 hat all dissolved plus the approximately 0.3 nmol kg(-1) of particulate iron (measured in the eastern

103 Additionally, NVP-AAM077 at 0.3 nmol perfused into the contralateral ventricle, consider

104 stasis upon vascular injury at a dose of 0.3 nmol/kg compared with 300 nmol/kg for FVIIa.

105 weight for WG compared with 1.8 nmol/g (12.3 nmol/g) dry weight for RG; P < 0.01)].

106 (OH)D concentrations (control: 55.8 +/- 12.3 nmol/L; EAR: 64.1 +/- 10.0 nmol/L; and RDA: 63.7 +/- 12.

107 tamin D2 biscuit group [Delta (95% CI): 15.3 nmol/L (7.4, 23.3 nmol/L) (P < 0.0003) and 16.0 nmol/L (

108 vitamin D2 juice group [Delta (95% CI): 16.3 nmol/L (8.4, 24.2 nmol/L) (P < 0.0001) and 16.9 nmol/L (

109 39.2 nmol/L [32.8-48.1] for Ratanakiri, 19.3 nmol/L [15.1-26.2] vs 66.2 nmol/L [49.9-83.0] for Preah

110 n ethnicity (adjusted mean difference: -19.3 nmol/L; 95% CI: -25.4, -13.2 nmol/L) and smoking (adjust

111 Samples containing 2-3 nmol Cl injected on-column were sufficient to achieve a

112 roup [Delta (95% CI): 15.3 nmol/L (7.4, 23.3 nmol/L) (P < 0.0003) and 16.0 nmol/L (8.0, 23.9 nmol/L)

113 mol/L [median (IQR): 23.5 nmol/L (13.3, 37.3 nmol/L)] and showed significant monthly variation (P < 0

114 and the placebo group [Delta (95% CI): 42.3 nmol/L (34.4, 50.2 nmol/L) (P < 0.0001) and 42.9 nmol/L

115 ical activity, with 0.63, 21.7, 2.6, and 6.3 nmol/L for two live and two abiotic reactors after 519 d

116 3 nmol IMP288, 30 h; and C5: 60 nmol TF2, 3 nmol IMP288, 30 h).

117 F2, 6 nmol IMP288, 42 h; C4: 120 nmol TF2, 3 nmol IMP288, 30 h; and C5: 60 nmol TF2, 3 nmol IMP288, 3

118 P <20 nmol/L, and insufficiency as PLP 20-30 nmol/L.

119 C-BMT-136088 specific binding were 73 +/- 30 nmol/kg and 28 +/- 12 nM, respectively.

120 re required to maintain concentrations >/=30 nmol/L during winter.

121 maintain 25(OH)D concentrations >25 and >30 nmol/L in 97.5% of adolescents were estimated to be 10.1

122 to 71-fold) prevalence of serum 25(OH)D <30 nmol/L than did white populations.

123 ectrometry and categorized as deficient (<30 nmol/l), insufficient (30-50 nmol/l), or adequate (>/=50

124 s had 25-hydroxyvitamin D concentrations <30 nmol/L.

125 y at a dose of 0.3 nmol/kg compared with 300 nmol/kg for FVIIa.

126 <7 nmol/L and RBC folate concentration <305 nmol/L derived with the use of a microbiologic assay), p

127 iciency when serum (<7 nmol/L) and RBC (<305 nmol/L) folate were considered, whereas a higher proport

128 OP(DTT) was measured for 196 d (mean=0.32 nmol/min/m(3), interquartile range=0.21).

129 (-1)) and receptor density (meningioma, 5-34 nmol.L(-1), and NETs, 7-35 nmol.L(-1)).

130 <10 nmol/L and RBC folate concentration <340 nmol/L derived with the use of an RPBA), and insufficien

131 (meningioma, 5-34 nmol.L(-1), and NETs, 7-35 nmol.L(-1)).

132 his diminished by approximately 50% (to 1.38 nmol per gram of brain tissue +/- 0.10 or 0.00011% of th

133 ated its basal ATPase activity from 21 to 38 nmol of Pi.mg(-1).min(-1), and ATPase activity was furth

134 categories: <20 nmol/L, 20-29 nmol/L, 30-39 nmol/L, 40-49 nmol/L, 50-59 nmol/L, 60-74 nmol/L, 75-99

135 ine concentration increased from 0.9 +/- 0.4 nmol l(-1) at SL to 2.7 +/- 1.5 nmol l(-1) at HA (P = 0.

136 ncreased from 49.2 +/- 12.0 to 56.6 +/- 12.4 nmol/L and from 51.7 +/- 13.4 to 63.9 +/- 10.6 nmol/L in

137 64.1 +/- 10.0 nmol/L; and RDA: 63.7 +/- 12.4 nmol/L; P < 0.05) than the control group.

138 95% CI: 1.4, 11.7 mug/L; P = 0.013) and 16.4 nmol/L (95% CI: 9.5, 21.4 nmol/L; P < 0.001), respective

139 = 0.013) and 16.4 nmol/L (95% CI: 9.5, 21.4 nmol/L; P < 0.001), respectively.

140 In mice, LV MRGlu was 17.9 +/- 4.4 nmol x min(-1) x g(-1) at baseline.

141 ures of the algal mat mixture exceeded 10(4) nmol/g.

142 ciation with values in categories between 40 nmol/L and 120 nmol/L.

143 ain 50% of adolescents at concentrations >40 nmol/L.

144 the proportions of persons with 25(OH)D <40 nmol/L were 14-18% (overall), 46-60% (non-Hispanic black

145 causes increased with decreasing 25(OH)D <40 nmol/L, while there was no association with values in ca

146 s not affected by the coadministration of 40 nmol ( approximately 5 mg/kg) of the respective other co

147 ively, 100 muL, 10 pmol total peptide +/- 40 nmol Tyr(4)-BBN: for in vivo GRPR blockade) in severe co

148 rations were 29 nmol/L (17-50 nmol/L) and 41 nmol/L (29-60 nmol/L), respectively (P < 0.001).

149 ian PLP, 3-HK, and XA concentrations were 41 nmol/L (IQR: 29-60 nmol/L), 40.1 nmol/L (IQR: 33.0-48.0

150 with elevated Lp(a) concentrations (125-437 nmol/L in cohort A; >/=438 nmol/L in cohort B) were rand

151 trations (125-437 nmol/L in cohort A; >/=438 nmol/L in cohort B) were randomly assigned (in a 1:1 rat

152 ount and pertaining activity to be 76 +/- 46 nmol (118 +/- 71 mug) and 4.2 +/- 1.8 GBq for meningioma

153 response of 25(OH)D reached a plateau at 46 nmol/L, there is uncertainty in estimating the vitamin D

154 oncentrations were 35.1 nmol/L (range: 21-47 nmol/L) and 956 nmol/L (range: 305-2319 nmol/L), respect

155 nce of 0.67 nmol/mmol (95% CI, -1.13 to 2.48 nmol/mmol; P = .46).

156 H)D increased from 48 nmol/L (95% CI: 47, 48 nmol/L) to 65 nmol/L (95% CI: 65, 66 nmol/L) (P < 0.001)

157 d 2011, the mean S-25(OH)D increased from 48 nmol/L (95% CI: 47, 48 nmol/L) to 65 nmol/L (95% CI: 65,

158 t significantly different in ATG+G-CSF (0.49 nmol/L/min) versus placebo (0.29 nmol/L/min).

159 brain, a mean +/- standard deviation of 2.49 nmol per gram of brain tissue +/- 0.30 or 0.00019% of th

160 20 nmol/L, 20-29 nmol/L, 30-39 nmol/L, 40-49 nmol/L, 50-59 nmol/L, 60-74 nmol/L, 75-99 nmol/L (refere

161 0.9 +/- 0.4 nmol l(-1) at SL to 2.7 +/- 1.5 nmol l(-1) at HA (P = 0.03).

162 um 25-hydroxyvitamin D concentrations (154.5 nmol/L vs. 15.2 nmol/L in active vs. placebo arms, respe

163 Very similar concentrations of LK (0.5-2.5 nmol/g tissue) were found in LanCL1 knock-out, TKO and w

164 was 27.7 +/- 18.9 nmol/L [median (IQR): 23.5 nmol/L (13.3, 37.3 nmol/L)] and showed significant month

165 1.5 nmol/L (IQR: 45.6-86.5 nmol/L), and 25.5 nmol/L (IQR: 17.2-40.0 nmol/L), respectively, in RTRs (a

166 red with 29 nmol/L (IQR: 17-50 nmol/L), 61.5 nmol/L (IQR: 45.6-86.5 nmol/L), and 25.5 nmol/L (IQR: 17

167 tched healthy controls (15.7 vs 49.5 vs 66.5 nmol/L; p = 0.0001).

168 : 17-50 nmol/L), 61.5 nmol/L (IQR: 45.6-86.5 nmol/L), and 25.5 nmol/L (IQR: 17.2-40.0 nmol/L), respec

169 ith lower IA risk (odds ratio = 0.93 for a 5 nmol/L difference; 95% CI 0.89, 0.97).

170 5(OH)D concentrations were 86.5 (33.5-155.5) nmol/L.

171 of inactive compound ( approximately 0.15-50 nmol) to the injected activity ( approximately 20 MBq fo

172 sma PLP concentrations were 29 nmol/L (17-50 nmol/L) and 41 nmol/L (29-60 nmol/L), respectively (P <

173 controls compared with 29 nmol/L (IQR: 17-50 nmol/L), 61.5 nmol/L (IQR: 45.6-86.5 nmol/L), and 25.5 n

174 maintain serum 25(OH)D concentrations >25-50 nmol/L, depending on the serum 25(OH)D threshold chosen.

175 n latitudes to maintain serum 25(OH)D >30-50 nmol/L depending on chosen serum 25(OH)D threshold.

176 deficient (<30 nmol/l), insufficient (30-50 nmol/l), or adequate (>/=50 nmol/l).

177 4.2 +/- 1.8 GBq for meningioma and 87 +/- 50 nmol (135 +/- 78 mug) and 5.1 +/- 2.8 GBq for NET patien

178 ed by cotreatment with the alphaAnalogue (50 nmol.kg(-1).d(-1), SC, at a dose selected for lack of lo

179 using 95% prediction intervals for 30 and 50 nmol S-25(OH)D/L, intakes of 6 and 20 mug/d are required

180 ove the proposed cutoffs (25, 30, 40, and 50 nmol/L) in white Danish children aged 4-8 y living at 55

181 portion of children with serum 25(OH)D >/=50 nmol/L during periods of minimal ultraviolet B radiation

182 In children with CKD, 25(OH)D >/=50 nmol/L was associated with greater preservation of renal

183 compared with those with high 25(OH)D (>/=50 nmol/L) who declined 314 mL, 246 mL, and 3.0%, respectiv

184 ufficient (30-50 nmol/l), or adequate (>/=50 nmol/l).

185 d, respectively, to maintain S-25(OH)D >/=50 nmol/L, whereas intakes of 6 and 14 mug/d, respectively,

186 ntrol group had 25(OH)D concentrations >/=50 nmol/L.

187 25-hydroxyvitamin D [S-25(OH)D; i.e., >/=50 nmol/L] during winter regardless of latitude and skin co

188 amin D status is sufficient [S-25(OH)D >/=50 nmol/L], and supplementation is generally not needed.

189 dations reached S-25(OH)D concentrations >50 nmol/L in 2011.The vitamin D status of the Finnish adult

190 uired to maintain 25(OH)D concentrations >50 nmol/L in 97.5% of adolescents, but it exceeded 30 mug/d

191 ), medium (100 nmol or 2300 mg), and low (50 nmol or 1150 mg) amounts of sodium for 30 d (crossover d

192 otein were not associated, but 25(OH)D </=50 nmol/L associated with higher diastolic BP (P=0.004).

193 droxyvitamin D [25(OH)D] concentration </=50 nmol/L) adults were randomly assigned to receive either

194 al" postdexamethasone cortisol levels (</=50 nmol/L) were associated with larger NFAT size and higher

195 ributable risk of 25(OH)D concentrations <50 nmol/L for preterm birth or small size for gestational a

196 Participants with low 25(OH)D (<50 nmol/L) had more decline in lung function measurements f

197 oncentration, averaged across pregnancy, <50 nmol/L) was not associated with changes in BMD or BMC.

198 Vitamin D inadequacy (<50 nmol/L) was related to higher education (P-trend < 0.01)

199 sted definition of vitamin D deficiency (<50 nmol/L), the prevalence was 40.4%.

200 ive protein <10 mg/L) and VDD as 25(OH)D <50 nmol/L.

201 having 25(OH)D concentrations lower than 50 nmol/L.

202 rformed over the concentration range 100-500 nmol/mol, with NO and NO2 reactants/calibrants diluted d

203 ol/d but was highly variable (range: 64-5358 nmol/d).

204 ation was lower in the rivaroxaban group (56 nmol/L, 95% CI 47-66 vs 86 nmol/L, 72-102, treatment eff

205 1 nmol/mmol (SD, 4.67 nmol/mmol) versus 7.58 nmol/mmol (SD, 6.17 nmol/mmol), with a mean difference o

206 in PC3 and PC3-TXR cells was 55.6 and 2,580 nmol/L, respectively, but decreased to 49.8 and 93.2 nmo

207 29 nmol/L, 30-39 nmol/L, 40-49 nmol/L, 50-59 nmol/L, 60-74 nmol/L, 75-99 nmol/L (reference), and >/=1

208 ectable in 99.9% of samples, was 2.6 +/- 1.6 nmol/L.

209 serum total testosterone increased from 10.6 nmol/L (SD 2.2) to 19.7 nmol/L (9.2) and free testostero

210 ol/L and from 51.7 +/- 13.4 to 63.9 +/- 10.6 nmol/L in the 10- and 20-mug/d groups, respectively, and

211 mol/L [49.9-83.0] for Preah Vihear, and 19.6 nmol/L [11.9-33.9] vs 81.1 nmol/L [61.3-113.1] for Pursa

212 difference: -7.0 nmol/L; 95% CI: -10.5, -3.6 nmol/L) were negative predictors of 25(OH)D.

213 2007-2010 the mean measured 25(OH)D was 5-6 nmol/L higher.

214 ebo group from 46.8 +/- 11.4 to 30.7 +/- 8.6 nmol/L (all P </= 0.001).

215 ized to receive grass allergen peptides at 6 nmol at 2-week intervals for a total of 8 doses (8x6Q2W)

216 T for comparably large doses, for example, 6 nmol (0.65 mg/kg) (68)Ga-aquibeprin per mouse (3.5 MBq/n

217 argeting time intervals (C1: 120 nmol TF2, 6 nmol IMP288, 24 h; C2: 120 nmol TF2, 6 nmol IMP288, 30 h

218 F2, 6 nmol IMP288, 24 h; C2: 120 nmol TF2, 6 nmol IMP288, 30 h; C3: 120 nmol TF2, 6 nmol IMP288, 42 h

219 F2, 6 nmol IMP288, 30 h; C3: 120 nmol TF2, 6 nmol IMP288, 42 h; C4: 120 nmol TF2, 3 nmol IMP288, 30 h

220 nmol/L (95% CI: 19, 21 nmol/L), which was 6 nmol/L higher than nonconsumers (n = 229) (14 nmol/L; 95

221 XA concentrations were 41 nmol/L (IQR: 29-60 nmol/L), 40.1 nmol/L (IQR: 33.0-48.0 nmol/L), and 19.1 n

222 9 nmol/L (17-50 nmol/L) and 41 nmol/L (29-60 nmol/L), respectively (P < 0.001).

223 thritis and low 25-hydroxyvitamin D (12.5-60 nmol/L) were enrolled from June 2010 to December 2011.

224 20 nmol TF2, 3 nmol IMP288, 30 h; and C5: 60 nmol TF2, 3 nmol IMP288, 30 h).

225 r caused the removal of total mercury by 600 nmol m(-2) and of methylmercury by 214 nmol m(-2) in the

226 upling and ROS excess occurred at PCoA > 600 nmol/mg mito prot, in both control and diabetic animals.

227 ean concentration of 25(OH)D in blood was 63 nmol/L (SD 24) at baseline, with 1534 (30%) having 25(OH

228 Surface CH4 flux decreased from 64 nmol m(-2) s(-1) in intact polygons to 7 nmol m(-2) s(-1

229 women: 36.88 +/- 4.11 vs men: 21.22 +/- 3.65 nmol/g protein, p = 0.007) was observed.

230 from 48 nmol/L (95% CI: 47, 48 nmol/L) to 65 nmol/L (95% CI: 65, 66 nmol/L) (P < 0.001).

231 47, 48 nmol/L) to 65 nmol/L (95% CI: 65, 66 nmol/L) (P < 0.001).

232 7 nmol/mmol), with a mean difference of 0.67 nmol/mmol (95% CI, -1.13 to 2.48 nmol/mmol; P = .46).

233 hour UFC excretion: 6.91 nmol/mmol (SD, 4.67 nmol/mmol) versus 7.58 nmol/mmol (SD, 6.17 nmol/mmol), w

234 216 +/- 14 nmol/mL (in Sweden) to 870 +/- 68 nmol/mL (in rural Gambia) (P < 0.05).

235 A higher precursor concentration (0.7 nmol) further increased labeling and quantitative yields

236 tlantic Bight (20 +/- 8.8 versus 2.2 +/- 1.7 nmol L(-1) d(-1) , p = 0.026) but not the Gulf of Alaska

237 ol/L (95% CI: -26.2, -7.1); CA vs. CC: -10.7 nmol/L (95% CI: -14.9, -6.5)).

238 ations of serum total testosterone were 10.7 nmol/L (SD 2.3) at baseline and 11.1 nmol/L (3.2) post-i

239 fidence interval for difference, 125.9-154.7 nmol/L; P < 0.001) but did not influence time to sputum

240 88 functional polymorphism (AA vs. CC: -16.7 nmol/L (95% CI: -26.2, -7.1); CA vs. CC: -10.7 nmol/L (9

241 increased from 10.6 nmol/L (SD 2.2) to 19.7 nmol/L (9.2) and free testosterone concentrations increa

242 ignificant (19.4 +/- 4.8 versus 12.0 +/- 2.7 nmol L(-1) d(-1) , p > 0.05).

243 SD concentration of 25(OH)D2 was 3.1 +/- 2.7 nmol/L, which was present in all samples.

244 ation and puncture, RvD2 ( approximately 2.7 nmol/mouse) significantly increased survival (>50%) of w

245 .8 nmol/L) (normal range, 0-4.9 mg/L [0-46.7 nmol/L]).

246 of age (e.g., serum folate concentration <7 nmol/L and RBC folate concentration <305 nmol/L derived

247 ce (<1%) of folate deficiency when serum (<7 nmol/L) and RBC (<305 nmol/L) folate were considered, wh

248 64 nmol m(-2) s(-1) in intact polygons to 7 nmol m(-2) s(-1) in degraded polygons, and stable isotop

249 eacetic acid levels were measured and were 7 nmol/L (343 microg/L) (high) and 2.9 mg per 24 hours (15

250 0046 h(-1), and the desorption rate was 4.71 nmol l(-1) s(-1).

251 es C-90 degrees C), tracer amount (0.11-0.74 nmol), and labeling time.

252 39 nmol/L, 40-49 nmol/L, 50-59 nmol/L, 60-74 nmol/L, 75-99 nmol/L (reference), and >/=100 nmol/L.

253 Healthy volunteers (Lp[a] >/=75 nmol/L) were randomly assigned to receive a single dose

254 (OH)D concentrations </=50 compared with >75 nmol/L.

255 nmol/g) dry weight for WG compared with 1.8 nmol/g (12.3 nmol/g) dry weight for RG; P < 0.01)].

256 l/L) (P < 0.0001) and 16.9 nmol/L (9.0, 24.8 nmol/L) (P < 0.0001)], and the placebo group [Delta (95%

257 a C-reactive protein value of 0.4 mg/L (3.8 nmol/L) (normal range, 0-4.9 mg/L [0-46.7 nmol/L]).

258 ection and quantification were 12.5 and 37.8 nmol/L adenine, respectively.

259 /L) (P < 0.0001) and 42.9 nmol/L (35.0, 50.8 nmol/L) (P < 0.0002)].With the use of a daily dose of vi

260 the WG diet compared with the RG diet [-6.8 nmol/g (13.0 nmol/g) dry weight for WG compared with 1.8

261 )D in the 3 groups, it was approximately 7-8 nmol/L lower in the control group than in the 2 groups w

262 trols) and high-dose subgroups (37.2 +/- 7.8 nmol x min(-1) x g(-1), P < 0.01 vs. controls, P < 0.05

263 L]) and C-reactive protein (97.1 mg/L [924.8 nmol/L]; normal level, <8 mg/L [<76.2 nmol/L]]) levels w

264 re treated with 4 GBq of (177)Lu activity/80 nmol of precursor, 6 GBq of (177)Lu activity/120 nmol of

265 oquine concentrations were 471, 688, and 809 nmol/L for standard-dose and 1040, 1494, and 1585 nmol/L

266 y excretion of menaquinones in feces was 850 nmol/d but was highly variable (range: 64-5358 nmol/d).

267 roxaban group (56 nmol/L, 95% CI 47-66 vs 86 nmol/L, 72-102, treatment effect 0.6, 95% CI 0.5-0.8, p=

268 ormal testosterone concentrations (3.47-13.9 nmol/L, or free testosterone <173 pmol/L) were randomly

269 l/L (8.4, 24.2 nmol/L) (P < 0.0001) and 16.9 nmol/L (9.0, 24.8 nmol/L) (P < 0.0001)], and the placebo

270 in D supplement use of >/=1,000 IU/day (18.9 nmol/L (95% confidence interval (CI): 16.1, 21.8) vs. no

271 entration for all subjects was 27.7 +/- 18.9 nmol/L [median (IQR): 23.5 nmol/L (13.3, 37.3 nmol/L)] a

272 rfluorohexanoic carboxylic acid (PFHxA - 2.9 nmol/L).

273 l/L) (P < 0.0003) and 16.0 nmol/L (8.0, 23.9 nmol/L) ( P < 0.0001)], the vitamin D2 juice group [Delt

274 8.0 nmol/L), and 19.1 nmol/L (IQR: 14.5-24.9 nmol/L), respectively, in healthy controls compared with

275 :3 fluorotelomer carboxylic acid (FTCA - 3.9 nmol/L) and perfluorohexanoic carboxylic acid (PFHxA - 2

276 olate at baseline (above the median, >/=33.9 nmol/L) had less improvement in cB-12 (P < 0.001) than d

277 centration (i.e., with a concentration <33.9 nmol/L).

278 e protein level was normal at 4.4 mg/L (41.9 nmol/L).

279 /L (34.4, 50.2 nmol/L) (P < 0.0001) and 42.9 nmol/L (35.0, 50.8 nmol/L) (P < 0.0002)].With the use of

280 4h): 27.7 +/- 7.9 compared with 58.4 +/- 7.9 nmol/L x h, respectively; P = 0.01].

281 this value in the standard-dose (27.9 +/- 9 nmol x min(-1) x g(-1), P < 0.05 vs. controls) and high-

282 9 y old (e.g., RBC folate concentration <906 nmol/L derived with the use of a microbiologic assay).

283 no difference in 24-hour UFC excretion: 6.91 nmol/mmol (SD, 4.67 nmol/mmol) versus 7.58 nmol/mmol (SD

284 re 35.1 nmol/L (range: 21-47 nmol/L) and 956 nmol/L (range: 305-2319 nmol/L), respectively.

285 49 nmol/L, 50-59 nmol/L, 60-74 nmol/L, 75-99 nmol/L (reference), and >/=100 nmol/L.

286 Results were obtained for eight 25(OH)D (nmol/L) categories: <20 nmol/L, 20-29 nmol/L, 30-39 nmol

287 tooth loss by category of baseline 25(OH)D (nmol/L) concentrations.

288 precursors were compared to total fluorine (nmol F/cm(2)) determined by particle-induced gamma ray e

289 ol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol specific activity) or total activity (30, 60, or 12

290 8% and specific activities of 326 +/- 20 MBq/nmol are obtained reproducibly.

291 q at high, 62 MBq/nmol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol specific activity) or total act

292 Lower values ranging from 150 to 0.4 MBq/nmol were adjusted by addition of inactive compound ( ap

293 A specific activity of 55.5 MBq/nmol (0.37 MBq/mug) was reproducibly obtained with [(89)

294 high radiochemical purity (>95%, 2.2-4.5 MBq/nmol).

295 mg/kg) (68)Ga-aquibeprin per mouse (3.5 MBq/nmol).

296 lations for specific (60 MBq at high, 62 MBq/nmol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol spec

297 d (>87%), high specific activity (>/=9.8 MBq/nmol), and purity (>99%).

298 /- 6054, n = 3, all values expressed as mean nmol/g protein +/- standard error of the mean, p = 0.040

299 ed 64 +/- 28% to 110 +/- 30% of the original nmol F/cm(2) as determined by PIGE, indicating that the

300 To achieve the detection of sub-nmol/L physiological levels of vitamin B12, our assay in

301 %, and 0.021-14%, respectively, of the total nmol F/cm(2) determined by PIGE.